Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Human medicines European public assessment report (EPAR): Orgovyx, relugolix, Date of authorisation: 29/04/2022, Revision: 12, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 12, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, Date of authorisation: 04/03/2013, Revision: 25, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Revision: 1, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Human medicines European public assessment report (EPAR): Cotellic, cobimetinib, Date of authorisation: 20/11/2015, Revision: 16, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Human medicines European public assessment report (EPAR): Zessly, infliximab, Date of authorisation: 18/05/2018, Revision: 15, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Human medicines European public assessment report (EPAR): Korjuny, catumaxomab, Date of authorisation: 10/02/2025, Revision: 3, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Date of authorisation: 13/03/2013, Revision: 12, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
Generic Drug Facilities, Sites and Organization Lists
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA
CDER Nitrosamine Impurity Acceptable Intake Limits
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA
EnviroServe Chemicals & Cleaners Ltd. - 674090 - 09/09/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA
Greco Gas, Inc. - 683090 - 08/12/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA
Zen Enterprises LLC - 678407 - 09/11/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA
Torrent Pharmaceuticals Limited - 585255 - 09/04/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.